Aerovate reports FY2022 net loss of $51.5M; cash runway into H2 2025

Jade Biosciences, Inc.

Net loss of $51.5M for FY2022 vs $23.0M in FY2021; R&D expenses $38.6M (up from $15.0M).
Cash, cash equivalents and investments $129.2M as of Dec 31, 2022; sufficient to fund operations into H2 2025.
IMPAHCT Phase 2b/3 trial of AV-101 for PAH ongoing; topline data expected Q4 2023 or Q1 2024.
Four patents issued in 2022; management team strengthened with four new SVPs.
Board appointed Donald Santel; expanded IP portfolio.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.6

Jade Biosciences, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 29, 2023, Aerovate Therapeutics, Inc. announced its financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001798749-23-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.